Neutrophil chemotaxis and serum chemotactic activity in systemic lupus erythematosus. 1978

I Alvarez, and J J Vazquez, and G Fontan, and A Gil, and J Barbado, and J A Ojeda

Neutrophil chemotaxis, random motility, serum chemotactic activity derived from complement activation by classical or alternative pathways, and the presence of serum inhibitors of chemotaxis were all studied in 24 patients affected by Systemic Lupus Erythematosus (SLE) and in an equal number of healthy control subjects. Statistical comparison between patients and controls indicated lower chemotactic activity in patient's serum when activated by the classical pathway, and the presence in some SLE patients of a heat-labile inhibitor of the chemoattractants. Low "classical pathway" chemotactic indexes were correlated with low C4 values, active nephritis and recurrent infections. The presence of heat-labile inhibitor was correlated with low values of C3. Our data suggest that defective neutrophil chemotaxis could be one of the mechanisms contributing to the high incidence of infections suffered by SLE patients. The importance of conducting separate studies on cell movement and on generation of serum chemotactic activities by classical and alternative pathways in SLE patients is discussed.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D011415 Complement Factor B A glycine-rich, heat-labile serum glycoprotein that contains a component of the C3 CONVERTASE ALTERNATE PATHWAY (C3bBb). Bb, a serine protease, is generated when factor B is cleaved by COMPLEMENT FACTOR D into Ba and Bb. C3 Proactivator,C3PA,Complement 3 Proactivator,Factor B,Properdin Factor B,Bb Fragment of Factor B,Complement Factor B Fragment, Bb,Complement Factor B, Alternative Pathway,Complement Factor B-Derived Fragment Bb,Complement Factor Ba,Complement Factor Bb,Complement Protein B,Complement Protein Factor B,Properdin Factor Ba,Properdin Factor Bb,Properdin Factor Bf,Properdin Factor Bf F1,Bb, Complement Factor,Complement Factor B Derived Fragment Bb,Factor B, Complement,Factor B, Properdin,Factor Ba, Complement,Factor Ba, Properdin,Factor Bb, Complement,Factor Bb, Properdin,Factor Bf, Properdin,Proactivator, C3,Proactivator, Complement 3,Protein B, Complement
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D002634 Chemotaxis, Leukocyte The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction. Leukotaxis,Leukocyte Chemotaxis
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003169 Complement Inactivator Proteins Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors. Complement Cytolysis Inhibiting Proteins,Complement Cytolysis Inhibitor Proteins,Complement Inactivating Proteins,Serum Complement Inactivators,Complement Inactivators, Serum,Inactivating Proteins, Complement,Inactivator Proteins, Complement,Inactivators, Serum Complement,Proteins, Complement Inactivating,Proteins, Complement Inactivator
D003170 Complement Pathway, Alternative Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Alternative Complement Pathway,Properdin Pathway,Alternative Complement Activation Pathway,Complement Activation Pathway, Alternative

Related Publications

I Alvarez, and J J Vazquez, and G Fontan, and A Gil, and J Barbado, and J A Ojeda
March 1974, Annals of the rheumatic diseases,
I Alvarez, and J J Vazquez, and G Fontan, and A Gil, and J Barbado, and J A Ojeda
January 2013, Acta reumatologica portuguesa,
I Alvarez, and J J Vazquez, and G Fontan, and A Gil, and J Barbado, and J A Ojeda
July 1959, Bollettino della Societa italiana di biologia sperimentale,
I Alvarez, and J J Vazquez, and G Fontan, and A Gil, and J Barbado, and J A Ojeda
June 1987, The Journal of rheumatology. Supplement,
I Alvarez, and J J Vazquez, and G Fontan, and A Gil, and J Barbado, and J A Ojeda
August 2011, The New England journal of medicine,
I Alvarez, and J J Vazquez, and G Fontan, and A Gil, and J Barbado, and J A Ojeda
July 1978, The Journal of clinical investigation,
I Alvarez, and J J Vazquez, and G Fontan, and A Gil, and J Barbado, and J A Ojeda
December 1979, Arthritis and rheumatism,
I Alvarez, and J J Vazquez, and G Fontan, and A Gil, and J Barbado, and J A Ojeda
April 2013, Journal of clinical & cellular immunology,
I Alvarez, and J J Vazquez, and G Fontan, and A Gil, and J Barbado, and J A Ojeda
January 1981, Clinical immunology and immunopathology,
I Alvarez, and J J Vazquez, and G Fontan, and A Gil, and J Barbado, and J A Ojeda
February 1991, Revista clinica espanola,
Copied contents to your clipboard!